These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7863833)

  • 1. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
    Rossini M; Gatti D; Zamberlan N; Braga V; Dorizzi R; Adami S
    J Bone Miner Res; 1994 Nov; 9(11):1833-7. PubMed ID: 7863833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
    Buffo L; Rossini M; Buoncristiano A; Girardello S; Zamberlan N; Diani F; Adami S
    Minerva Ginecol; 1996 Jun; 48(6):263-72. PubMed ID: 8927288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.
    Hirsch LJ; Pryor-Tillotson S
    Ann Ital Med Int; 1995 Oct; 10 Suppl():22S-28S. PubMed ID: 8562261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
    Cheng ZQ; Yin W; Fan JY; Ma TJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
    Bettembuk P; Balogh A
    Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction.
    Motoie H; Nakamura T; O'uchi N; Nishikawa H; Kanoh H; Abe T; Kawashima H
    J Bone Miner Res; 1995 Jun; 10(6):910-20. PubMed ID: 7572315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.